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Summary
Spontaneous mutants of Mycobacterium tuberculo-
sis that were resistant to the anti-tuberculosis drugs
ethionamide and isoniazid were isolated and found
to map to mshA, a gene encoding the ﬁrst enzyme
involved in the biosynthesis of mycothiol, a major
low-molecular-weight thiol in M. tuberculosis. Seven
independent missense or frameshift mutations
within mshA were identiﬁed and characterized.
Precise null deletion mutations of the mshA gene
were generated by specialized transduction in three
different strains of M. tuberculosis. The mshA dele-
tion mutants were defective in mycothiol biosynthe-
sis, were only ethionamide-resistant and required
catalase to grow. Biochemical studies suggested
that the mechanism of ethionamide resistance in
mshA mutants was likely due to a defect in ethiona-
mide activation. In vivo, a mycothiol-deﬁcient strain
grew normally in immunodeﬁcient mice, but was
slightly defective for growth in immunocompetent
mice. Mutations in mshA demonstrate the non-
essentiality of mycothiol for growth in vitro and in
vivo, and provide a novel mechanism of ethionamide
resistance in M. tuberculosis.
Introduction
The increase in drug resistance in Mycobacterium tuber-
culosis clinical isolates has impeded the full success of
tuberculosis (TB) control. The WHO estimates that 4.3%
of the newly and previously treated TB cases are multi-
drug-resistant (MDR) meaning that these strains are
resistant to at least the two best anti-TB drugs: isoniazid
(INH) and rifampicin (Zignol et al., 2006). Alarmingly,
there has been an emergence of M. tuberculosis strains
resistant to four to seven TB drugs (termed XDR-TB for
extensively drug-resistant TB) that have been associated
with the rapid death of HIV-infected individuals (Gandhi
et al., 2006; Shah et al., 2007).Amore effective treatment
for both MDR- and XDR-TB strains requires rapid detec-
tion and therefore understanding of all the mechanisms
leading to drug resistance.
Isoniazid, the cornerstone of front-line TB treatment,
shares a common target with the second-line TB drug
ethionamide (ETH). Both INH and ETH are pro-drugs
that require activation to form adducts with NAD to sub-
sequently inhibit InhA, the NADH-dependent enoyl-ACP
reductase (Dessen et al., 1995; Quemard et al., 1995) of
the fatty acid biosynthesis type II system (Marrakchi et al.,
2000). However, activation of INH and of ETH occurs
through different pathways. INH is activated by the katG-
encoded catalase peroxidase (Zhang et al., 1992; Wilming
and Johnsson, 1999) to form the INH-NAD adduct
(Rozwarski et al., 1998). ETH, on the other hand,
is activated by the ethA-encoded mono-oxygenase
(Baulard et al., 2000; DeBarber et al., 2000; Vannelli et al.,
2002) to yield the ETH-NAD adduct (Wang et al., 2007).
Mutations in either activator confer resistance to INH or
ETH respectively (Piatek et al., 2000; Morlock et al., 2003;
Ramaswamy et al., 2003; Hazbon et al., 2006).
Co-resistance to INH and ETH can be mediated by muta-
tions that alter the InhA target so as to prevent the INH-
NAD or the ETH-NAD adduct from binding (Vilcheze et al.,
2006), by mutations that cause InhA overexpression
(Larsen et al., 2002; Vilcheze et al., 2006) or by mutations
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therebycompetitivelyinhibitingthebindingoftheINH-NAD
and ETH-NAD adducts to InhA (Miesel et al., 1998;
Vilcheze et al., 2005). While the majority of clinical isolates
resistant to INH or ETH have been shown to map to the
activator genes (katG, ethA)o rt h einhA target, current
studies still show that up to 22% of the INH-resistant
M. tuberculosis clinical isolates have no mutations in the
genes known to be involved in INH or ETH resistance
(Hazbon et al., 2006). In this study, to identify novel muta-
tions conferring INH and ETH resistance, we isolated
spontaneous mutants of M. tuberculosis in vitro and found
that they map to mshA, a gene encoding a glycosyltrans-
ferase involved in mycothiol biosynthesis, suggesting that
mshA was non-essential.Additional genetic and biochemi-
cal studies demonstrated that mycothiol biosynthesis is
required for ETH susceptibility in M. tuberculosis. Further-
more, in vivo studies showed that mycothiol is not required
for growth in mice.
Results and discussion
Spontaneous mutants of M. tuberculosis, co-resistant to
INH and ETH, map to mshA
Numerous studies have demonstrated that there exist
strains of M. tuberculosis that are resistant to INH and
do not have mutations in the genes associated with
INH resistance (katG, inhA structural gene and promoter,
ndh) (Telenti et al., 1997; Piatek et al., 2000;
Ramaswamy et al., 2003; Cardoso et al., 2004; Hazbon
et al., 2006). To eliminate the majority of spontaneous
mutants of M. tuberculosis that are singly resistant to INH
and map to katG, we chose to isolate mutants that were
co-resistant to INH and its structural analogue ETH.
Samples of three independent M. tuberculosis H37Rv
cultures were plated on media containing low concentra-
tions of both INH and ETH [ 4-fold the minimum inhibi-
tory concentration (MIC)]. Seven mutants were isolated at
low frequencies (1–4 ¥ 10-8). DNA sequence analysis of
targeted genes in these seven strains revealed the
absence of mutations in the genes known to mediate
co-resistance to INH and ETH, namely inhA (the gene or
its promoter region) and ndh. This analysis provided the
evidence that these strains possessed mutations that
conferred INH and ETH resistance and had not been
previously identiﬁed in M. tuberculosis. The mutants were
transformed with a cosmid genomic library of the drug-
susceptible M. tuberculosis parent. The frequency of
transformation was extremely low for most of the mutants
(less than 100 transformants per transformation), and
only one mutant, mc24936, which had the lowest level of
INH resistance, yielded more than 1000 transformants.
The cosmid transformants were screened for restoration
of INH and ETH susceptibility. One potential comple-
menting cosmid was isolated, sequenced and shown to
contain the mshA gene, a gene characterized as mediat-
ing the ﬁrst step in the biosynthesis of mycothiol (Newton
et al., 2003; 2006), a key thiol in the family of Actino-
mycetes bacteria (Newton et al., 1996). A link between
mycothiol biosynthesis and resistance to INH and
ETH had been previously established in Mycobacterium
smegmatis when transposon mutants in mshA were
found to be resistant to INH (more than 25-fold) and ETH
(sixfold) (Newton et al., 1999; 2003; Rawat et al., 2003).
Subsequent sequence analysis of mc24936 and the other
mutants showed that all the M. tuberculosis H37Rv
mutants had missense, nonsense or frameshift mutations
in mshA (Table 1). The mshA mutants had various levels
of resistance to INH (2- to 16-fold) and ETH (four- to
eightfold) (Table 2). This is the ﬁrst report that mshA
mutations confer co-resistance to INH and ETH in
M. tuberculosis.
Table 1. M. tuberculosis strains used in this study.
Strain Genotype
mshA allele characterization
Mutant generation Source Nucleotide Amino acid
H37Rv mshA1 –– Trudeau Institute
mc
24931 mshA3 c382t Stop codon AA128 Spontaneous mutant of H37Rv This work
mc
24932 mshA4 c817t R273C Spontaneous mutant of H37Rv This work
mc
24933 mshA5 g895t G299C Spontaneous mutant of H37Rv This work
mc
24934 mshA6 c991t Stop codon AA331 Spontaneous mutant of H37Rv This work
mc
24935 mshA7 g1067a G356D Spontaneous mutant of H37Rv This work
mc
24936 mshA8 a1082c E361A Spontaneous mutant of H37Rv This work
mc
24937 mshA9 a1242del Frameshift Spontaneous mutant of H37Rv This work
mc
24938 mshA10 DmshA Specialized transduction with phAE222 This work
CDC1551 mshA1 –– CSU
mc
24939 mshA10 DmshA Specialized transduction with phAE222 This work
Erdman mshA2 a332g N111S Trudeau Institute
mc
24942 mshA10 DmshA Specialized transduction with phAE222 This work
CSU, Colorado State University.
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the synthesis of mycothiol
The glycosyltransferase MshAis the ﬁrst step in mycothiol
biosynthesis that leads to the formation of N-acetyl-
glucosamine inositol (Newton and Fahey, 2002; Newton
et al., 2006). The biosynthesis of mycothiol requires ﬁve
enzymes to form N-acetyl-cysteine glucosamine inositol or
mycothiol from inositol-1-phosphate and UDP-N-acetyl-
glucosamine: the glycosyltransferase MshA, the phos-
phatase MshA2, the deacetylase MshB, the cysteine
ligase MshC and the acetyltransferase MshD (Fig. 1). To
analysetheeffectsofthediversemutationsinmshAonthe
biosynthesis of mycothiol, the levels of mycothiol were
measured in all the mutants using ﬂuorescent high-
performance liquid chromatography (HPLC) assay
(Newton et al., 2000a). We found a dramatic reduction
(83% to undetectable levels) in the concentration of myco-
thiol compared with wild type (Fig. 2A). As a control, we
also measured the mycothiol level in an INH- and ETH-
resistant M. tuberculosis inhA mutant, mc24911 (Vilcheze
et al., 2006), and found that this mutant had a concentra-
tion of mycothiol similar to that in wild type. Complemen-
tation of the mutants with pMV361::mshA, an integrative
plasmid containing only the mshA gene of M. tuberculosis
driven by the hsp60 promoter, restored mycothiol biosyn-
thesis in all the mutants (Fig. 2B). This conﬁrms that the
defect in mycothiol biosynthesis was due to the mutations
in mshA. Although mycothiol has been suggested to be
essential for the growth of M. tuberculosis (Sareen et al.,
2003), our data show that M. tuberculosis strains that do
not produce mycothiol are viable.
Comparison of the MshA structures of M. tuberculosis
and Corynebacterium glutamicum establishes a
rationale for the inactivation of MshA in the mutants
Given the sequence identity (45.9%) between M. tuber-
culosis MshA and Corynebacterium glutamicum MshA
(CgMshA) whose structure was recently determined
(Vetting et al., 2008), the monomeric homology model of
Table 2. INH and ETH minimum inhibitory concentrations (MICs).
Strain
MIC (mg l
-1)
MIC (mg l
-1)
pMV361::mshA
INH ETH INH ETH
H37Rv 0.06 2.5 0.06 2.5
mc
24931 0.6 20 0.06 2.5
mc
24932 0.4 10 0.06 2.5
mc
24933 0.6 20 0.12 2.5
mc
24934 1 10 0.5 2.5
mc
24935 1 10 0.06 2.5
mc
24936 0.12 20 0.06 2.5
mc
24937 0.5 20 0.12 2.5
mc
24938 0.06 > 20 0.06 2.5
CDC1551 0.06 2.5
mc
24939 0.12 > 20 0.06 2.5
Erdman 0.06 2.5
mc
24942 0.06 15 0.06 2.5
Fig. 1. Mycothiol biosynthesis pathway. The ﬁrst step in the biosynthesis of mycothiol (MSH) is the coupling of UDP-N-acetyl
glucosamine and inositol-1-phosphate followed by dephosphorylation, carried out by the glycosyltransferase MshA and the phosphatase
MshA2 respectively. The deacetylase MshB removes the acetyl group on the glucosamine which allows for the addition of a cysteine
group on the free amino group by the ligase MshC. The last step is the acetylation of the cysteine amino group by the acetyltransferase
MshD.
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with the UDP-complexed CgMshA (PDB code 3C4Q)
as template (Lund et al., 2002). Superimposition of
the model of M. tuberculosis MshA (consisting of Arg46–
Ile445) and the chain B from UDP/inositol-phosphate-
bound CgMshA (PDB code 3C4V) yields an RMSD of
0.65 Å, indicating a high homology between each other
(Fig. 3A).
Four of the mshA mutants have single amino acid muta-
tion (Table 1). These four amino acids (Arg273, Gly299,
Gly356 and Glu361) are conserved in CgMshA (as
Arg231, Gly263, Gly319 and Glu324) (Fig. 3C). Each of
these amino acids plays an important role in either the
substrate binding or the domain interaction (Fig. 3B). The
side-chain amines ofArg273 interact with the b-phosphate
of UDP via hydrogen bonding. This arginine is also one
of the major determinants of the orientation of the inositol-
phosphate as its side-chain lies against the face of
inositol. Gly299 is not in the vicinity of the active site, but
should be important for the protein stability as the next
residue, Gly300, forms the only interdomain hydrogen
bond with Gly61 (Fig. 3A). Although not directly seen in
the model, Gly356 was proposed to be involved in the
binding of the N-acetyl-glucosamine moiety which shall be
transferred from UDP to inositol (Vetting et al., 2008). In
mc24936, the Glu361Ala mutation removes the side-chain
carboxylate that forms hydrogen bonds with the 2′- and
3′-hydroxyls from the ribose moiety of UDP, which could
result in the inactivation of MshA.
The other mshA mutants had either nonsense or frame-
shift mutations (Fig. 3C). In mc24931 and mc24934, the
nonsense mutations caused the loss of active-site
elements. In mc24937, the truncation of the protein was
close to the C-terminus and the active site was unlikely to
be affected. Herein the inactivation of MshA could be
explained by the protein’s characteristic folding. Based
on the homology model of MshA, each monomer is
composed of N-terminal and C-terminal domains.
Towards the end of C-terminus, a large a-helix spanning
Cys409 to Ile445 crosses back to the N-terminal, which
is likely to stabilize the overall folding of the protein.
Therefore the mutations within this a-helix, such as in
mc24937, would detrimentally affect the conformation of
MshA leading to its inactivation.
Fig. 2. Mycothiol contents in M. tuberculosis mshA mutants and complemented strains. The strains were grown to stationary phase.
Mycothiol contents were measured in triplicate for the M. tuberculosis mshA point mutants (A) and their complemented strains (B) as well as
for the mshA null mutants (C) and their complemented strains (D) as described in Experimental procedures.c= pMV361::mshA.
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overexpression nor by increased NADH/NAD+ ratios in
mshA mutants of M. tuberculosis
Although co-resistance to INH and ETH had been pre-
viously identiﬁed in M. smegmatis mshA transposon
mutants (Rawat et al., 2003), no mechanism of resistance
had been identiﬁed to link mycothiol biosynthesis with INH
and ETH resistance (Koledin et al., 2002; Rawat et al.,
2003). Previously, co-resistance to INH and ETH has been
shown to be conferred by three different mechanisms: (i)
structural mutations in the inhA target (Banerjee et al.,
Fig. 3. A. Ribbon representation of the superimposed M. tuberculosis MshA model (green) and CgMshA structure (blue) complexed with
UDP/inositol-phosphate. Both UDP and inositol-phosphate are shown as stick with transparent surface. Four amino acids, whose mutation led
to M. tuberculosis MshA inactivation, are represented as CPK structures and labelled accordingly.
B. Active-site architecture of the superimposed MshA structures shown in (A). UDP and inositol-phosphate are shown as ball and stick. The
four amino acid mutations R273, G299, G356 and E361, highlighted in (A), are shown as stick in white scheme, and the conserved residues
in CgMshA are in white scheme, and the conserved residues in CgMshA are in blue scheme. Hydrogen bonds between the side-chain amines
of Arg273 and the b-phosphate of UDP, as well as those between the side-chain carboxylate of Glu361 and the ribosyl hydroxyl groups of
UDP are shown as black dotted lines. The residue numbers are for M. tuberculosis MshA.
C. Alignment of the M. tuberculosis and C. glutamicum mshA sequences. The mutations identiﬁed in the M. tuberculosis mshA mutants are
indicated. The four amino acid changes are in bold. The stop codons or frameshift are pointed by arrows. The residues in the a-helix crossing
from C-terminal to N-terminal domain are underlined.
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(Larsenet al.,2002;Vilchezeet al.,2006),or(iii)increased
NADH/NAD+ ratios resulting in higher concentration of
NADH, which competitively inhibits the binding of the
INH-NAD or ETH-NAD adduct to InhA(Miesel et al., 1998;
Vilcheze et al., 2005). We reasoned that it was highly
unlikely that the gene product of mshA directly interacted
withInhA.However,itwaspossiblethatmutationsinmshA
caused overexpression of inhA or altered the NADH/NAD+
ratios inside the M. tuberculosis cells. To test these possi-
bilities, we ﬁrst measured the inhA mRNA levels in three
mshA mutants and their complemented strains using a
molecular beacon reverse transcription polymerase chain
reaction (RT-PCR) assay (Larsen et al., 2002). In contrast
to the P-15 mabAinhA mutation, which has been shown to
confer 10-fold overexpression of the inhA mRNA(Vilcheze
et al., 2006), all three of these mshA mutants revealed no
increase in inhA mRNA levels (Fig. 4A) and so resistance
to ETH and INH was not due to InhA overexpression. We
also measured the NAD+ and NADH concentrations in
each of the mutants and found that the mutants had mostly
lower NADH concentrations compared with wild type
(Fig. 4B), demonstrating that the co-resistance to INH and
ETH was not due to an increase in the NADH/NAD+ ratio.
The sum of this work suggested that the mshA mutations
must mediate a novel mechanism of resistance.
Isolation of precise null deletions of mshA in various
M. tuberculosis strains
Introduction of a wild-type copy of mshA restored ETH
sensitivity (Table 2) and mycothiol content (Fig. 2B) in all
the mshA mutants, but a subset of the mutants (3/7)
did not regain INH susceptibility (Table 2). We reasoned
that these strains must have acquired secondary
mutations to compensate for the loss of mycothiol and
that these mutations were also mediating the INH
resistance. Although further studies will be needed to
identify such mutations, we could hypothesize from these
complementation studies that the loss of the mshA gene
would mostly confer ETH resistance. To test this possibil-
ity, precise null mutants of mshA were generated in three
reference strains of M. tuberculosis using specialized
transduction (Bardarov et al., 2002) (Fig. S1, Table 1).
The H37Rv, CDC1551 and the Erdman DmshA strains
were resistant to ETH, but only the CDC1551 DmshA
strain showed a twofold increase in INH MIC (Table 2).
Previously, deletions in mshB (Buchmeier et al., 2003)
and mshD (Buchmeier et al., 2006) had been isolated in
M. tuberculosis, and only the mshB mutant was shown to
be INH-resistant. Our data show that the main drug
resistance phenotype of the M. tuberculosis mshA null
mutant is resistance to ETH.
All three M. tuberculosis mshA deletion mutants failed
to produce any detectable level of mycothiol (Fig. 2C).
Complementation of the null mutants with pMV361::mshA
restored ETH susceptibility (Table 2) and mycothiol pro-
duction (Fig. 2D). To rule out the possibility that the lack of
mycothiol might cause a compensatory phenotype, we
measured total thiol concentrations in the cells and found
that the null mutants’ thiol concentrations were reduced
by 53%, 77% and 82% in M. tuberculosis H37Rv,
CDC1551 and Erdman respectively.
A previous study had suggested that the mshA gene
was essential in M. tuberculosis (Buchmeier and Fahey,
2006). The discovery of frameshift mutations within the
Fig. 4. Possible mechanisms of INH and
ETH resistance in mshA mutants.
A. Three mshA point mutants and their
complemented strains, as well as wild type,
were either treated or not treated with INH
(1 mg l
-1) for 4 h before the inhA mRNA levels
were measured. inhA levels were normalized
to sigA expression. The experiment was
performed in triplicate.
B. NADH and NAD
+ concentrations in mshA
point mutants. The strains were grown to log
phase. NADH and NAD
+ were extracted and
measured spectrophotometrically, as
described in Experimental procedures.
c = pMV361::mshA.
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null mshA deletions in three independent M. tuberculosis
strains, demonstrates that mshA is not an essential gene
in M. tuberculosis. Although both studies attempted to
generate null mshA mutants in M. tuberculosis using spe-
cialized transduction, it would be difficult to extrapolate
why one was successful and the other one was not. We
can only note that the M. tuberculosis mshA deletion
strains were obtained after a very long incubation at 37°C
(8 weeks). Furthermore, this study also conﬁrms that
mycothiol is the major thiol in M. tuberculosis as it repre-
sents more than 50% of the total thiol concentration in
M. tuberculosis.
The mshA mutants require catalase to grow
As mycothiol has been suggested to be essential for the
growth of M. tuberculosis (Sareen et al., 2003), we tested
whether the mshA mutants had any growth defect in vitro.
We observed no differences in growth rates in liquid media
for the mshA point mutants and the null mutants (Fig. 5A).
A previous study showed that an M. tuberculosis DmshD
strain producing 1% of mycothiol compared with wild
type required OADC (oleic acid-bovine albumin-dextrose-
catalase-sodium chloride) to grow on plate (Buchmeier
et al., 2006). We tested the M. tuberculosis DmshA
mutants on Middlebrook 7H10 plates supplemented with
glycerol and either OADC or ADS (bovine albumin-
dextrose-sodium chloride). The mutants did not grow on
the ADS plates but grew well on OADC plates. We then
tested whether the mutants required either oleic acid
and/or beef liver catalase to grow, as these are found in
OADC supplement but not inADS.Adding oleic acid to the
ADS plate did not allow for growth of the mutants, but
the addition of beef liver catalase was sufficient to restore
growth on plates (Fig. 5B). The role of catalase in the
OADC supplement is to eliminate toxic peroxides in
the media. As mycothiol is involved in the detoxiﬁcation of
Fig. 5. Growth of M. tuberculosis mshA mutants in vitro.
A. Growth in liquid media (Middlebrook 7H9 supplemented with 0.2% glycerol, OADC and 0.05% tyloxapol) of four mshA point mutants (left)
or two DmshA mutants and their complemented strains (right).
B. Growth on solid media of H37Rv DmshA (top right), H37Rv DmshA pMV361::mshA (top left), CDC1551 DmshA (bottom right) and
CDC1551 DmshA pMV361::mshA (bottom left) on Middlebrook 7H10 plates supplemented with 0.2% glycerol and ADS, ADS + beef liver
catalase, ADS + oleic acid or OADC.
c = pMV361::mshA.
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(Rawatet al.,2007),itisnotsurprisingthatM. tuberculosis
mutants producing no mycothiol require catalase for
protection against toxic reactive oxygen intermediates.
Mycolic acid biosynthesis is not inhibited by ETH
treatment of mshA mutants
The death of the tubercle bacillus following treatment with
INH correlates with inhibition of the biosynthesis of the
long-chain a-alkyl b-hydroxy fatty acids (up to 90 carbons
in length) called mycolic acids, which are a major constitu-
ent of the mycobacterial cell wall (Winder and Collins,
1970; Takayama et al., 1972). ETH, based on its similarity
to INH, has also been predicted and shown to inhibit
mycolic acid biosynthesis (Winder et al., 1971; Quemard
et al., 1992; Baulard et al., 2000). As mycothiol is not
known to be involved in the FASII pathway, the resistance
mediated by mshA could suggest that the lethal event
occurs in some redox function. If so, it may be possible
that INH and ETH treatment of mshA mutants does not
confer resistance to mycolic acid inhibition by ETH or
INH. Fatty acids were extracted from the wild-type
M. tuberculosis strains, the DmshA mutants and the
DmshA-complemented strains following INH or ETH treat-
ment, and derivatized to their methyl esters. Analysis by
thin-layer chromatography (TLC) allowed for the separa-
tion between the short-chain fatty acid (up to 26 carbons
in length) methyl esters (FAMEs) and the long-chain
mycolic acid methyl esters (MAMEs) (Fig. 6). Treatment
of the wild-type M. tuberculosis strains and the DmshA-
complemented strains with INH or ETH resulted in inhibi-
tion of mycolic acid biosynthesis as shown by the absence
of MAMEs on TLC. In contrast, the DmshA mutants were
resistant to mycolic acid inhibition upon treatment with
ETH, but not with INH (Fig. 6).
The mshA mutants support the premise that ETH inhib-
its mycolic acid biosynthesis as the mshA mutants were
resistant to mycolic acid biosynthesis inhibition upon
ETH treatment. Previous studies have shown four differ-
ent mechanisms of ETH resistance in tubercle bacilli,
including: (i) target modiﬁcation (Banerjee et al., 1994;
Vilcheze et al., 2006), (ii) target overexpression (Larsen
et al., 2002), (iii) intracellular NADH/NAD+ ratio alteration
(Miesel et al., 1998; Vilcheze et al., 2005) and (iv) ETH
activator inactivation (Baulard et al., 2000; DeBarber
et al., 2000). All four of these phenomena are consistent
with ETH being a pro-drug that is activated to form an
adduct with NAD and this ETH-NAD adduct inhibits InhA,
which results in mycolic acid biosynthesis inhibition
(Vilcheze and Jacobs, 2007b; Wang et al., 2007).
To address the mechanism by which mutations in mshA
confer ETH resistance, we can now rule out a number of
these known mechanisms. Quantitative PCR analysis
demonstrated that the inhA mRNA was not upregulated
thereby suggesting InhA was not overexpressed. More-
over, we measured NADH/NAD+ ratios and found no
increase in NADH concentration in the mshA mutants. All
of these data, coupled with the lack of resistance to INH
and the high resistance to ETH, allow us to hypothesize
that mycothiol plays a role either in the activation step of
ETH or in the formation of the ETH-NAD adduct.
Mycothiol promotes ETH activation by the ethA-encoded
mono-oxygenase
As the null mutants showed low (twofold the MIC) to no
resistance to INH but showed a high level of resistance to
ETH ( 6-fold the MIC), we therefore postulated that
mycothiol could be involved in either ETH activation or
ETH-NAD adduct formation in M. tuberculosis. ETH is
activated by the NADPH-speciﬁc FAD-containing mono-
oxygenase EthA (Baulard et al., 2000; DeBarber et al.,
2000; Vannelli et al., 2002). We tested the NADPH-
dependent mono-oxygenation of ETH by EthAin the pres-
ence of mycothiol, and observed an increase in the rate of
reaction directly proportional to the increase in mycothiol
concentration, suggesting that mycothiol plays a role in
Fig. 6. Fatty acid methyl ester (FAME) and mycolic acid methyl ester (MAME) analyses of DmshA mutants. M. tuberculosis wild-type strains,
DmshA and complemented strains were treated with INH (0.5 mg l
-1) or ETH (15 mg l
-1) for 4 h, and then labelled with [1-
14C]-acetate for 20 h.
Fatty acids and mycolic acids were saponiﬁed, methylated, extracted and separated by thin-layer chromatography.
14C-labelled FAMEs and
MAMEs were detected by autoradioragraphy after 36 h exposure at -80°C. c = pMV361::mshA.
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ETH-NAD adduct (Table 3). Furthermore, replacing myco-
thiol by a different thiol, such as reduced glutathione,
had no effect on the oxidation rate of NADPH (data not
shown). This suggests that the increase in EthA activity
upon the addition of mycothiol is speciﬁc to mycothiol, and
does not occur in the presence of another thiol. To test if
mycothiol was also required for the formation of the ETH-
NAD adduct, the rate of inhibition of InhA by ETH in the
presence of NAD+, NADPH, EthA and mycothiol was also
measured. No formation of the ETH-NAD adduct was
observed in these conditions (data not shown), which
suggests that mycothiol is not involved in the formation of
the ETH-NAD adduct. The mycothiol-dependent increase
in the rate of NADPH conversion during the activation of
ETH by EthA suggests that mycothiol promotes the
activation of ETH by EthA. Two other anti-TB drugs, isoxyl
and thiacetazone, are also activated by EthA(Dover et al.,
2007). We therefore tested if the mshA mutants (null and
point mutants) were also resistant to isoxyl and thiaceta-
zone and found that they were fully sensitive to both drugs
(data not shown). This implies that mycothiol is solely
involved in the activation of ETH. We could hypothesize
that mycothiol either stabilizes the intermediates formed
upon activation of ETH or forms a complex with the active
form of ETH, which allows for the formation of the ETH-
NAD adduct. More in-depth studies are necessary to fully
understand which role mycothiol plays in the activation
step.
Mycothiol is not required for M. tuberculosis growth
in vivo
Mycothiol has been postulated to be essential for
M. tuberculosis growth in vivo. The mshA mutant
mc24936, which does not synthesize mycothiol, was
chosen to study the survival of immunocompetent
C57Bl/6 mice and immunocompromised SCID mice
following aerosol infection. No signiﬁcant difference in
survival was observed between mice infected with
wild-type M. tuberculosis and the mycothiol-deﬁcient
mshA mutant (Fig. 7A). Interestingly, the SCID mice
infected with the complemented strain (complementation
was done with a replicative plasmid expressing mshA)
survived 30 days longer than the parent strain. In vivo
growth of the mshA mutant mc24936 in the lungs of immu-
nocompromised and immunocompetent mice was also
measured. In SCID mice, the mshA mutant and the
wild-type M. tuberculosis strains grew at the same rate,
while the complemented strain grew slightly more slowly,
which might explain the differences in survival rates
(Fig. 7B). In C57Bl/6 mice, the mshA mutant growth was
slightly defective after 3 weeks but at week 8 of infection
the mycobacterial burden in the lung was comparable
between the mutant and the wild-type strain (Fig. 7B).
Our demonstration that M. tuberculosis DmshA strain
requires catalase to grow in vitro, but not in mice suggests
that either the host is not an oxidatively stressed environ-
ment or growth in mice induces alternative thiols that may
compensate for the absence of mycothiol. Further studies
will be required to solve this paradox.
Concluding remarks
A novel mechanism of ETH resistance has been dis-
covered in M. tuberculosis which demonstrates that
mycothiol plays a role in the pro-drug activation by the
ethA-encoded mono-oxygenase. As mono-oxygenases
are known to mediate detoxifying reactions, it is reason-
able to assume that mycothiol plays a role in other, as yet
unidentiﬁed, detoxifying reactions. This resistance is a
loss of function and is consistent with mycothiol playing a
role in the ETH activation process. The requirement for
mycothiol in the inhibition of mycolic acid biosynthesis by
ETH supports the model that ETH, upon activation with
EthA, forms an adduct with NAD, which subsequently
inhibits InhA. We hypothesize that novel drugs that
bypass this activation step and target InhA directly should
be developed as they could lead to the killing of
M. tuberculosis cells.
Interestingly, the ﬁrst study by Dubos and Middlebrook
(1947) of a medium to grow tubercle bacilli (now referred
as Middlebrook 7H9 with OADC supplement) did not
add beef liver catalase. A few years later, the discovery
by Middlebrook that INH-resistant mutants of M. tuber-
culosis were catalase-negative (Middlebrook, 1954;
Middlebrook et al., 1954) initiated the need to add cata-
lase to the media to isolate and grow M. tuberculosis
INH-resistant strains. Our study shows that there exists
at least one class of INH- or ETH-resistant M. tubercu-
losis mutants that would not readily grow on media
without catalase and may provide an explanation why
certain clinical isolates are difficult to grow. Furthermore,
the ﬁnding that three mshA mutants, when comple-
mented with a wild-type copy of mshA, still possessed a
low-level resistance to INH but were fully sensitive to
ETH suggests that these mutants must have acquired a
secondary mutation. Therefore, there may exist addi-
Table 3. The effect of mycothiol on EthA activity.
[Mycothiol]
(mM)
[NADPH] s
-1
mMs
-1
NADPH/EthA
mmol s
-1 (mg protein)
-1
0 0.0071 1.24 ¥ 10
-4
4.38 0.0074 1.29 ¥ 10
-4
17.5 0.0094 1.64 ¥ 10
-4
26.2 0.0111 1.94 ¥ 10
-4
43.8 0.0127 2.23 ¥ 10
-4
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ered involving other redox pathways.
Experimental procedures
Bacterial strains, plasmids, phages and media
The M. tuberculosis strains (H37Rv, CDC1551 and Erdman)
were obtained from laboratory stocks. The strains were
grown in Middlebrook 7H9 medium (Difco) supplemented
with 10% (v/v) OADC enrichment (Difco), 0.2% (v/v) glycerol
and 0.05% (v/v) tyloxapol. The solid medium used was the
same as described above, with the addition of 1.5% (w/v)
agar. The plasmids pMV261 and pMV361 were obtained from
laboratory stocks. Hygromycin was used at concentrations of
50 mg l
-1 for mycobacteria and 150 mg l
-1 for Escherichia
coli. Kanamycin was used at concentrations of 20 mg l
-1 for
mycobacteria and 40 mg l
-1 for E. coli.
Isolation of INH- and ETH-resistant spontaneous
mutants
Mycobacterium tuberculosis H37Rv mutants were isolated
from non-mutagenized cultures grown in the media described
above. The cultures were incubated by shaking at 37°C to
late log phase. Ten-fold serial dilutions were then plated
on agar plates (media described above) containing INH
(0.2 mgm l
-1) and ETH (5 or 10 mgm l
-1). The plates were then
incubated at 37°C for 6 weeks.
MIC determination
The strains were grown to an OD600 ª 1.0. Ten-fold serial
dilutions were plated on plates containing INH (0, 0.1, 0.2,
0.25, 0.3, 0.4, 0.5, 0.6, 0.8, 1 mgm l
-1) or ETH (0, 2.5, 5, 10,
15, 20 mgm l
-1). The MIC was determined as the concentra-
tion of drug that reduced the number of colony-forming units
(cfu) ml
-1 by 99%. MICs were also determined using the MTT
assay (Martin et al., 2005).
Determination of NADH and NAD+ cellular
concentrations
Mycobacterium tuberculosis strains were grown to log phase.
The cultures (12 ml) were spun, and the cell pellets were
re-suspended in 0.2 M HCl (1 ml, NAD
+ extraction) or 0.2 M
NaOH (1 ml, NADH extraction). After 10 min at 55°C, the
suspensions were cooled to 0°C, and neutralized by adding
0.1 M NaOH (1 ml, NAD
+ extraction) or 0.1 M HCl (1 ml,
NADH extraction).After centrifugation, the supernatants were
collected, ﬁlter-sterilized and frozen. The concentration of
Fig. 7. In vivo growth of wild-type M. tuberculosis H37Rv, mc
24936 and its complemented strain mc
24936-c following low-dose (ª10
2 cfu)
aerosol infection.
A. Survival in immunocompetent C57Bl/6 mice or immunocompromised SCID mice.
B. Growth in the lungs of C57Bl/6 mice or SCID mice.
c = pMV261::mshA.
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+ (or NADH) was obtained by measuring spectrop-
hotometrically the rate of 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide reduction by the yeast type II
alcohol dehydrogenase in the presence of phenazine etho-
sulphate at 570 nm, which is proportional to the concentration
of nucleotide (Leonardo et al., 1996; San et al., 2002).
Quantiﬁcation of the inhA expression levels
Total RNA extractions, cDNA synthesis and quantitative PCR
with molecular beacons were performed in triplicate, as
described previously (Larsen et al., 2002). inhA levels were
normalized to sigA expression.
Quantiﬁcation of mycothiol contents
The M. tuberculosis strains (45 ml) were grown to stationary
phase for 2 weeks. Samples (9 ml) were transferred into
conical tubes and centrifuged. The cell pellets were
re-suspended in either 0.5 ml of mBBr reagent (20 mM
HEPES pH 8 + 2 mM monobromobimane in acetonitrile/
water 1/1, v/v) or 0.5 ml of NEM reagent (20 mM HEPES
pH 8 + 5m MN-ethylmaleimide in acetonitrile/water 1/1, v/v)).
The suspensions were heated at 60°C for 15 min and spun
down. The supernatants (0.5 ml) were treated with 5 M
methane sulphonic acid (2 ml) and frozen. The samples were
subjected to HPLC analysis as described earlier (Newton
et al., 2000b).
Quantiﬁcation of the total thiol concentration
Mycobacterium tuberculosis strains were grown to stationary
phase and spun down. The cell pellets were washed with
PBS and then re-suspended in 1 ml of PBS. Glass beads
were added (0.2 ml), the suspensions were lysed using the
Thermo Scientiﬁc FastPrep machine (45 s, speed 6, three
times) and spun down, and the supernatants were ﬁlter-
sterilized. The total thiol concentration was obtained using
Ellman’s reagent by measuring spectrophotometrically, at
412 nm, a 1 ml solution containing 50 mM Tris (pH 8.0),
5 mM 5,5′-dithiobis(2-nitrobenzoic acid) (10 ml), and the
lysate to quantify (e412 nm 2-nitro-5-thiobenzoate anion is
14150 M
-1 cm
-1).
Construction of the DmshA strains
Mycobacterium tuberculosis mshA was replaced by a hygro-
mycin cassette using the specialized transduction system
previously described (Bardarov et al., 2002). Brieﬂy, a 1 kb
region ﬂanking the left and right sides of mshA was PCR-
ampliﬁed from M. tuberculosis genomic DNA using the fol-
lowing primers (the cloning sites are underlined):
LL TTTTTTTTCCATAAATTGGGGGCCGCGCTGACCTCAC
TG,
LR TTTTTTTTCCATTTCTTGGGACGGCGCTGGGCGATCA
AC,
RL TTTTTTTTCCATAGATTGGCCTGGTAGCGGTGGGCAA
GC,
RR TTTTTTTTCCATCTTTTGGGCGGGCCGATCGCGACC
TTG.
The PCR fragments were cut with Van91I and cloned into
p004S. The resulting cosmid was sequenced before digest-
ing with PacI. The linearized cosmid was ligated to the PacI-
cut shuttle phasmid phAE159 and the resulting phasmid,
phAE222, was packaged in vitro (Gigapack II, Stratagene).
High-titre phage lysates were used to transduce M. tubercu-
losis H37Rv, CDC1551 and Erdman as described previously
(Vilcheze et al., 2006). The plates were incubated at 37°C for
8 weeks. The transductants were checked for the deletion
of mshA by Southern analysis (the genomic DNA of the
transductants was cut with BglII and probed with the right
ﬂank of mshA) (Fig. S1).
Complementation of the mshA mutants
The wild-type M. tuberculosis mshA gene was ampliﬁed from
M. tuberculosis chromosomal DNA using the following
primers: mshAF CGGCAGCTGTTCGGTTCCTGCAAGGAT
GG (PvuII site underlined), mshAR GCGGAATTCTCGGC
AAGGAGGAAGTCACG (EcoRI site underlined). The PCR
product was digested with PvuII and EcoRI and ligated to
the replicative E. coli mycobacterial shuttle vector pMV261
(Stover et al., 1991) (http://www.aecom.yu.edu/tbresearch/
Resources/Vectors/261.html) restricted by PvuII and EcoRI
or the integrative E. coli mycobacterial shuttle vector pMV361
(http://www.aecom.yu.edu/tbresearch/Resources/Vectors/
361.html) (Stover et al., 1991) restricted by PvuII and EcoRI.
The mshA mutant strains were then transformed with the
plasmid pMV361::mshA or pMV261::mshA, using the follow-
ing protocol. The strains (20 ml of cultures) were grown at
37°C to an OD600 ª 0.8, washed twice with a 10% aqueous
glycerol solution and re-suspended in 0.4 ml of a 10%
aqueous glycerol solution. The cell suspensions (0.175 ml)
were added to the plasmid (2 ml) and electroporated (2.5 kV,
25 mFd, 1000 W). Medium (1 ml) was added, and the suspen-
sion was incubated at 37°C for 24 h and plated on Middle-
brook plates containing kanamycin (20 mg l
-1). The plates
were incubated at 37°C for 6 weeks.
Analysis of FAMEs and MAMEs
Mycobacterium tuberculosis strains were grown to log phase,
diluted to an OD600 ª 0.3, treated with INH (0.5 mg l
-1)o rE T H
(15 mg l
-1) or no drug for 4 h, and then labelled with [1-
14C]-
acetate (10 mCi) for 20 h at 37°C. The cultures were spun
down and washed once with water. The cell pellets were
saponiﬁed, methylated, extracted and analysed by TLC using
hexane/ethyl acetate 95/5 as the elution system (three elu-
tions were performed) (Vilcheze and Jacobs, 2007a).
EthA enzymatic activity assay
The his-tagged EthA was produced, as previously described
(Dover et al., 2007). The activity of EthA was determined by
monitoring the absorbance decrease of NADPH at 340 nm
(e340 nm = 6.22 mM
-1 cm
-1). All the reactions were catalysed by
~1 mM EthA and performed in 50 mM Tris/HCl, pH 7.5.
Double reciprocal plots were used to determine the kcat of the
oxidation of NADPH. For measuring the effect of mycothiol,
reaction mixtures contained 200 mM NADPH and varying
mycothiol concentrations.
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SCID mice and C57Bl/6 mice (Jackson Laboratories) were
infected via the aerosol route using a 10
6 cfu ml
-1 mycobac-
terial suspension in PBS containing 0.05% Tween 80 and
0.04% antifoam. Three mice from each group were sacriﬁced
after 24 h of infection and lung homogenates were plated on
Middlebrook 7H10 plates containing the appropriate antibiotic
to determine the initial infection dose. At 1, 3 and 8 weeks
post infection, three mice were sacriﬁced to determine the
bacterial burden in the lung, spleen and liver. Five mice were
left for survival experiments.
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